Andere talen Perseus Proteomics Inc.

Aandelen

4882

JP3836800007

Beurs gesloten - Japan Exchange Andere beurzen 08:00:00 31-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
325 ^JPY	+5,18%		+1,56%	-47,41%

10/05	Perseus Proteomics Inc. kondigt uitstel aan voor het einde van de Fase I klinische studie voor Polycythemia Vera	CI
14/02	Perseus Proteomics Inc. rapporteert resultaten voor de negen maanden eindigend op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	10/05
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023	14/02
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	02/02
Perseus Proteomics Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	13/11
Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV)	20-10-23
Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/Reagents	11-10-23
Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning Technology	27-09-23
Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell Leukemia	22-09-23
Perseus Proteomics, Inc. Announces MOU Agreement on Joint Research on Super-Neutralizing Antibody with University of Toyama and Toyama Prefecture	29-08-23
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	14-08-23
Perseus Proteomics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	14-08-23
Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003	29-05-23
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	12-05-23
Perseus Proteomics Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	12-05-23
Perseus Proteomics Inc. Updates Financial Forecast for the Year 2022	25-04-23
Perseus Proteomics Inc. Announces That PMDA Has Finished Investigation of the Clinical Trial Notification of the Phase I/II Investigator-Led Clinical Trial	27-03-23
Perseus Proteomics Inc. Submits the Clinical Trial Notification of the Phase I/II Investigator-Led Clinical Trial Among Aggressive Nk-Cell Leukemia Patients Using In-Development Anti-Transferrin Receptor Antibody PPMX-T003 as A Therapeutic to the PMDA by Hiroshima University Hospital	15-03-23
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2022	13-02-23
Perseus Proteomics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	13-02-23
Perseus Proteomics Inc. Announces Extension of Phase I Clinical Trial of PPMX-T003 among Polycythemia Vera Patients	07-02-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Perseus Proteomics Inc.

Aandelen

4882

JP3836800007

Andere talen

Filters